PT-141 (Bremelanotide): Evidence, Uses & Clinics

Common contexts

• Referenced in some hormone optimisation clinic listings in the context of sexual health pathways.
• Clinics may include PT-141 within broader men's or women's health programmes.
• It is usually discussed within targeted symptom pathways rather than broad longevity packages.

Safety information

• Suitability varies significantly by individual health profile.
• Only pursue through a clinic with a structured intake and clinician assessment process.
• Ask how the clinic evaluates contraindications, expectations, and follow-up care.

Clear intro

PT-141 pages attract users comparing sexual-health options. The key questions are whether a clinic uses the approved Vyleesi product or a compounded version, how suitability is assessed, and how side effects are managed.

Who this is for

This page is useful for people researching sexual-health, men's-health, women's-health, and hormone-optimisation clinics that reference PT-141 or bremelanotide.

What to ask before choosing a clinic

• Are you prescribing the FDA-approved Vyleesi product or a compounded version — and why?
• How do you assess suitability, and what side effects should I expect?
• What does the consultation, follow-up, and pricing include?

Pricing and red flags

PT-141 pricing varies by whether the approved product or a compounded version is used and what support is bundled. Compare clinical oversight, not just the headline number.

• Treating PT-141 as a casual 'enhancement' rather than a treatment with a specific approved indication.
• No clarity on whether it's the approved Vyleesi product or a compounded version.
• No discussion of side effects, suitability, or follow-up.

What is PT-141?

PT-141, also known as bremelanotide, is a synthetic melanocortin-receptor agonist developed for sexual dysfunction. It is unusual among directory peptides because it has an approved form: in the United States the FDA approved it as Vyleesi (a 1.75 mg subcutaneous self-injection) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT phase 3 trials. That FDA-approved product is different from the 'research peptide' PT-141 sold online, which sits in a legal grey area. In the United Kingdom bremelanotide is not a widely licensed product, and compounded PT-141 would be treated by the MHRA as unlicensed. On clinic directories PT-141 usually appears in sexual-health and hormone-optimisation contexts.

How it works

PT-141 acts on melanocortin receptors in the central nervous system, influencing pathways linked to sexual desire and arousal. This is a different mechanism from erectile-dysfunction medicines such as sildenafil, which work on blood flow — PT-141 is described as acting on the brain's 'desire' pathway rather than the vascular one. For someone comparing clinics, the more useful questions are whether the provider is using the FDA-approved Vyleesi or a compounded version, why, and how they assess suitability and side effects.

Cost overview

Pricing depends heavily on whether a clinic uses the FDA-approved Vyleesi product or a compounded version, and on whether the consult, assessment, and follow-up are bundled. Compare what clinical oversight is included rather than the headline figure, and ask which form is being prescribed. See the peptide therapy cost guide.

What to expect from clinics

• A credible clinic should be clear about whether it is discussing the FDA-approved Vyleesi product or a compounded/unlicensed version, and why.
• Expect a proper assessment of your history, goals, and suitability, plus clear discussion of side effects (such as nausea and transient blood-pressure changes) before any treatment.
• Be cautious of providers that treat PT-141 as a casual enhancement rather than a treatment with a specific approved indication and a clear risk profile.

Safety considerations

In its FDA-approved Vyleesi form, PT-141 has a defined indication (HSDD in premenopausal women) and a known side-effect profile that includes nausea and transient increases in blood pressure; it is not suitable for everyone, including people with uncontrolled high blood pressure or cardiovascular disease. Compounded or off-label use carries additional uncertainty. It should only be considered with a licensed clinician who can assess suitability, explain risks, and manage follow-up. This page does not recommend PT-141 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.